The control of organ size growth is one of the most fundamental aspects of life. In the past two decades, a highly conserved Hippo signaling pathway has been identified as a key molecular mechanism for governing organ size regulation. In the middle of this pathway is a kinase cascade that negatively regulates the downstream component Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ)/Yorkie through phosphorylation. Phosphorylation of YAP/TAZ/Yorkie promotes its cytoplasmic localization, leads to cell apoptosis and restricts organ size overgrowth. When the Hippo pathway is inactivated, YAP/TAZ/Yorkie translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. In this review, we will focus on the structural and functional studies on the downstream transcription factor TEAD and its coactivator YAP.
INTRODUCTION
The size of organisms on the earth, even the size of cells within an organism, varies remarkably. Cell growth, proliferation and apoptosis together define cell size and number to control organ size (Conlon and Raff, 1999) . If left unrestricted, cell proliferation can lead to uncontrolled organ size growth, which in turn results in diseases such as cancer. There are currently several pathways known to mediate the majority of cell fate decisions in metazoans, such as Notch, transforming growth factor β (TGF-β), Hedgehog, Janus kinase (JAK)/ signal transducer and activator of transcription (STAT), and most recently, the Hippo pathway (for reviews, see Barolo and Posakony, 2002; Pan, 2007) . The Hippo pathway was initially discovered in Drosophila through mosaic genetic screens with the key components sharing a similar overgrowth mutant phenotype (Justice et al., 1995; Xu et al., 1995; Kango-Singh et al., 2002; Tapon et al., 2002; Harvey et al., 2003; Pantalacci et al., 2003; Wu et al., 2003) . The prevailing model that has emerged from genetic and biochemical studies consists of three components, namely, a set of upstream regulatory factors (Ds, Ft, Ex, Mer and Kibra), the core kinase cassette (Hpo, Sav, Wts and Mats) and the downstream transcriptional machinery (Yki and Sd) (Fig. 1) . All the components are well conserved in mammals and comprise of Fat4 (Ft homolog), FRMD6 (Ex homolog), NF2 (Mer homolog), Mst1/2 (Hpo homolog), WW45 (Sav homolog), Lats1/2 (Wts homolog), Mob1 (Mats homolog), YAP and TAZ (Yki homologs) and TEAD (Sd homolog) (for reviews, see Zeng and Hong, 2008; Zhao et al., 2010) (Fig. 1) .
The Hippo pathway got its name from Hippo (Hpo), one of the two kinases that forms part of the core kinase module. The C-terminal domain of the STE20-like Hpo kinase associates with the N-terminal domain of its adaptor protein, Salvador (Sav), a WW-domain-containing protein, which acts as a scaffold to assemble the entire signaling complex containing Hpo and Warts (Wts), an NRD (nuclear Dbf2-related) family protein kinase (Harvey et al., 2003; Udan et al., 2003) (Fig. 2) . Upon autophosphorylation, Hpo/Sav phosphorylates Sav and Wts, resulting in Sav stabilization (Pantalacci et al., 2003; Wu et al., 2003) . The coiled-coil domain of Sav, SARAH, has been implicated in Hpo binding, although the cooperative nature between the N terminus and SARAH domain of Sav for binding to the C terminus of Hpo and regulating its activity is still unclear (Harvey et al., 2003; Scheel and Hofmann, 2003; Wu et al., 2003) (Fig. 2) . Wts also interacts directly with the two WW domains of Sav through its five PPXY motifs (Tapon et al., 2002) (Fig. 2) . Additionally, Hpo phosphorylates Mats (Mob as tumor suppressor), resulting in an increased affinity for Wts and Mats in turn activates Wts to phosphorylate the downstream transcriptional coactivator Yki at three HXRXXS consensus motifs (Praskova et al., 2008) . Phosphorylation of Yki at S168 creates a binding site for 14-3-3 proteins and leads to its cytoplasmic localization and subsequent inactivation (Basu et al., 2003; Dong et al., 2007; Zhao et al., 2007; Oh and Irvine, 2008; . Phosphorylation on the S111 and S250 sites of Yki also influences Yki activity in vivo, albeit via a mechanism different from 14-3-3 sequestration and cytoplasmic retention Ren et al., 2010) .
Yki can also be regulated by a phosphorylation-independent mode wherein Yki directly binds to Expanded (Ex) to prevent Yki from translocating into the nucleus (Badouel et al., 2009 ). The interaction between Yki and Ex is mediated by the two WW domains of Yki and three PPXY consensus motifs of Ex, all five of which are critical for efficient binding (Badouel et al., 2009; (Fig. 2 and 3) . Furthermore, Yki phosphorylation on S168 is dispensable for Ex binding (Badouel et al., 2009) . Ex has been demonstrated to regulate growth by directly inhibiting Yki via a reduction of the levels of Yki in the nucleus to inhibit an overgrowth phenotype, both in vitro and in vivo (Badouel et al., 2009 ). However it has been shown that when 14-3-3-dependent-sequestration of Yki is silenced, Yki still accumulates in the nucleus, indicating that phosphorylation-independent inhibition of Yki remains a minor mode of regulation.
The roles of signaling components upstream of Hpo have only recently been established. Hpo and Sav are directly regulated by a protein complex consisting of Ex, Mer and Kibra . Kibra contains two WW domains, the first of which mediates the interaction between Kibra and the RXPPXY motif of Ex, while the second WW domain has been postulated to be important for dimerization with Sav (Genevet et al., 2010; Yu et al., 2010) (Fig. 2) . The N-and C-terminal fragments of Kibra are responsible for association with Mer (Genevet et al., 2010) (Fig. 2) . The N-terminal half of Mer, which is composed mostly of the FERM domain, is required for interaction with Sav via a FERM binding consensus motif (FBM) in the N terminus of Sav (Fig. 2) . Mutation of the FBM abrogates not only Sav/Mer interaction, but also Mer-induced phosphorylation of Sav . Both the N-(containing the FERM domain) and C-terminal halves of Ex can associate with Hpo, while the SARAH domain of Hpo is essential for Ex interaction (Fig. 2) . Kibra, Mer and Ex colocalize to the apical membrane domain of epithelial cells, and function as a protein complex to regulate the Hippo signaling pathway. Two mechanisms have Figure 1 . Working model of the Hippo pathway in Drosophila. The Hippo pathway is affected by the upstream regulators consisting of membrane proteins Ft, Ds, and Crumbs, and the submembrane proteins Ex, Mer and Kibra. Hippo signaling involves a series of phosphorylation events mediated by the core kinase machinery consisting of Hpo, Sav, Wts and Mats, which leads to the phosphorylation of Yki and subsequent sequestration by 14-3-3 proteins, excluding it from the nucleus and its normal function of activating the transcription factor Sd. Non-phosphorylated Yki associates with Sd to form a transcription complex that will drive the expression of target genes that ultimately promote cell proliferation and cancer development. Arrowed and blunted lines indicate activation and inhibition respectively; dashed arrows indicate undetermined biochemical mechanism(s); question marks denote unknown component(s).
been proposed to explain the role of Fat in activation of the Hippo pathway. First, Fat, a transmembrane tumor suppressor, may be responsible for transducing growth signals to Ex in response to binding of Dachsous (Ds), thereby controlling Ex protein levels. Ft has also been found to colocalize with Ex in vivo, and hence may also be required for Ex membrane localization at apical junctions (Bennett and Harvey, 2006; Cho et al., 2006; Silva et al., 2006; Willecke et al., 2006; Tyler and Baker, 2007) . Although Ds interacts with Ft and is regarded as the ligand of Ft, both have been suggested to act in parallel to regulate tissue size (Willecke et al., 2006 ), thereby adding a further level of complexity. In the second proposed mode of regulation, Fat controls the protein levels of Wts through the myosin Dachs, which links Wts to proteins that promote proteolytic degradation of Wts (Cho et al., 2006; Feng and Irvine, 2007) . Both Ft and Ds can be further modulated by binding of Lowfat (Lft) and in the case of Ft, also regulated by phosphorylation by Discs Overgrown (Dco). In mammals, although Ft and Ex homologs (Fat4 and FRMD6) exist, their functional significance remains unclear; NF2 (Mer homolog) however retains some effect on the Hippo pathway. NF2 is not only dramatically downregulated in human mesotheliomas and gliomas, re-expression of NF2 in glioma cells inhibits cell proliferation and promotes apoptosis (Bianchi et al., 1994; Lau et al., 2008; Yokoyama et al., 2008) . In particular, NF2 has been suggested to regulate the phosphorylation state of YAP and in turn, its transcriptional activity (Yokoyama et al., 2008) .
TEAD/TEF FAMILY TRANSCRIPTIONAL FACTORS
The Transcription Enhancer Factor (TEAD/TEF) family of transcriptional factors is the mammalian homolog of Drosophila Sd sharing an evolutionarily conserved DNA binding TEA domain (Fig. 3A) . All four TEAD members (TEAD1-4) are ubiquitously expressed in mice and humans, but their pattern of expression and downstream target genes depend on the developmental stage and cellular context (Yockey et al., 1996; Kaneko et al., 1997; Jacquemin et al., 1998; Kaneko and DePamphilis, 1998) . The N-termini and prolinerich regions that are the most divergent between the four family members may account for their differences in activities. In gene knockout studies, while TEAD2 knockout mice appeared normal, TEAD1/TEAD2 double knockout mouse embryos displayed reduced cell proliferation and increased apoptosis, and experienced lethality around embryonic day 9.5 with severe growth defects and morphological abnormalities, suggesting that TEAD1 plays a more important proliferative role in development ). An earlier genetic study provided direct evidence for the involvement of TEAD1 in human disease. A missense mutation (Y421H) of TEAD1 was observed in sufferers of human Sveinsson's chorioretinal atrophy (SCRA), an autosomal dominant eye disease characterized by symmetric lesions radiating from the optic disc involving the retina and choroid (Fossdal et al., 2004) . This conserved residue was found to be defective in YAP and TAZ binding when mutated (Kitagawa, 2007) . Recent biochemical and genetic studies have established TEAD as a key downstream mediator of YAP (mammalian homolog of Yki) activity and distribution in Hippo signaling Zhao et al., 2008; Zhang et al., 2009 ). TEAD1 has also been implicated in prostate and pancreatic cancer (Hucl et al., 2007; Kwon et al., 2007; Knight et al., 2008) . . The abbreviations used are as follows: TEA, transcription enhancer factor; YAP, Yes-associated protein; Pro-rich, Proline-rich region; SH3, SRC homology 3 domain; PDZ, post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (DlgA), zonula occludens-1 protein (zo-1). (B) Crystal structure of mouse TEAD4 (green) complexed with mouse YAP (orange) (Protein Data Bank (PDB) accession code 3JUA) . The PXX f P motif is highlighted. (C) Crystal structure of human TEAD1 (green) complexed with human YAP (orange) (PDB accession code 3KYS) . (D) Crystal structure of human TEAD2 (green) (PDB accession code 3L15) (Tian et al., 2010) .
It has recently emerged that TEAD4 contributes to the fate of cell lineage specification by regulating trophectoderm function, but not inner cell mass specification (Yagi et al., 2007; Nishioka et al., 2008) . The Hippo pathway was shown to regulate differential signaling between the outside and inside cells of the preimplantation mouse embryo. In the outside cells, the Hippo kinase module is inactivated, allowing YAP to localize to the nuclei and activate TEAD4 transcription. Whereas in the inside cells, YAP is phosphorylated by Lats and sequestered in the cytoplasm (Nishioka et al., 2009 ). TEAD4 transcript levels have also been found to be amplified in breast (Richardson et al., 2006; Adélaïde et al., 2007; Han et al., 2008) , testicular (Almstrup et al., 2004; Skotheim et al., 2006) , brain (Weber et al., 1996; Ehrbrecht et al., 2006) , ovarian (Nowee et al., 2007) , throat (Rodriguez et al., 2005) , and head and neck (Singh et al., 2001) cancers. Soft agar assays further support TEAD4's possible role as an oncogenic protein during cancer development. TEAD4 overexpression resulted in an increase in transformation ability of MCF10A and NIH3T3 cells (Chan et al., 2009; Chen et al., 2010) .
YAP AND TAZ TRANSCRIPTIONAL CO-ACTIVATORS
YAP is the mammalian homolog of Yki and has been found to be able to functionally rescue Yki mutations in Drosophila (Huang et al., 2005) . The domain organization of YAP consists of an N-terminal proline-rich region, a TEAD binding domain, two tandem WW domains, an SH3 binding motif, a coiled-coil domain, a transcription activation domain and a Cterminal PDZ binding motif (Fig. 3A) . YAP is a potent growth promoter and overexpression of YAP increases organ size in Drosophila and saturation cell density of NIH3T3 cells (Zhao et al., 2007) . Several lines of evidence have indicated that YAP is a candidate oncogenic protein in mammalian cells. First, yap has been observed in the human chromosome 11q22 amplicon, a hallmark of several human cancers (Overholtzer et al., 2006; Zender et al., 2006) . Secondly, YAP is overexpressed and has increased nuclear localization in multiple types of human tumors, including colonic, lung, ovarian, hepatocellular, prostate, pancreatic, gastric and oral carcinomas (Baldwin et al., 2005; Snijders et al., 2005; LamHimlin et al., 2006; Modena et al., 2006; Dong et al., 2007; Zhao et al., 2007; Steinhardt et al., 2008; Yokoyama et al., 2008; Wang et al., 2010) . Third, overexpression of YAP in immortalized epithelial MCF10A cells induced epithelialmesenchymal transition (EMT), which is often associated with cancer stem cell property and cancer metastasis (Overholtzer et al., 2006; Polyak and Weinberg, 2009 ). Finally, YAP was found to cooperate with Myc oncogene to stimulate tumor growth in nude mice (Zender et al., 2006) . Further support for YAP being an oncogenic protein comes from observations that transgenic mice with liver-specific YAP overexpression showed a dramatic increase in liver size and eventually developed tumors (Camargo et al., 2007; Dong et al., 2007) .
The paralog of YAP, TAZ, was originally identified as a 14-3-3 binding protein (Kanai et al., 2000) . It has a similar domain structure to YAP, with the exception of the proline-rich region, the second WW domain and the SH3 binding motif. Similar to YAP, TAZ induces EMT, increases cell migration and invasion by mediating TEAD transcriptional activity (Chan et al., 2008; Lei et al., 2008) . A recent study demonstrates that TAZ regulates expression of the EMT transcription factor zinc finger E-box binding homeobox 1 (ZEB1) to control retinal pigment epithelial cell proliferation and differentiation by binding to the ZEB1 promoter (Liu et al., 2010) . Consequently, translocation of TAZ-TEAD1 complex into the nucleus was associated with a loss of intercellular contact, while knockdown of TAZ prevented proliferation and EMT. There is also evidence that TAZ may function as a co-activator of the MyoD transcription factor to promote expression of MyoD target genes to enhance myogenic differentiation (Jeong et al., 2010) . In addition, a link between TAZ and Wnt signaling was discovered recently when it was shown that the Hippo pathway is able to restrict Wnt/β-catenin signaling by promoting an interaction between TAZ and Disheveled (DVL) in the cytoplasm (Varelas et al., 2010) . Interestingly, YAP and TAZ have also been implicated in the maintenance of stem cell pluripotency. An earlier seminal work by Yaffe and colleagues demonstrated the role of TAZ as a regulator of mesenchymal stem cell differentiation by promoting osteoblast differentiation, which is dependent on Runx2-mediated gene transcription (Hong et al., 2005) . Recent data indicate that TAZ is essential to maintain the expression of pluripotency markers Oct4 and Nanog in human embryonic stem cells by regulating Smad nuclear shuttling (Varelas et al., 2010) . Further support for the notion that the Hippo signaling pathway is linked to pluripotency maintenance comes from the evidence that YAP mediates bone morphogenetic protein (BMP) target gene expression in mouse embryonic stem cells (Alarcon et al., 2009) .
TAZ is regulated in a similar way to YAP. While YAP is inactivated through Lats phosphorylation at serine 127 and subsequent cytoplasmic retention (Zhao et al., 2007; Hao et al., 2008) , TAZ undergoes phosphorylation at serine 89 (Lei et al., 2008) . Mutagenesis of this residue to alanine greatly enhances the oncogenic behavior of TAZ. Conversely, mutations of TAZ residues involved in TEAD binding abrogated TAZ-mediated transformation, indicating that TEADs modulate the ability of TAZ to promote cell proliferation, EMT and oncogenesis (Chan et al., 2009; Zhang et al., 2009; Chen et al., 2010) . Furthermore, the observations that YAP and TAZ knockout mice show different phenotypes suggest that YAP and TAZ do not compensate each other and may have distinct regulatory events in cellular and/or developmental processes (Morin-Kensicki et al. 2006; Hossain et al. 2007; Makita et al. 2008 ).
THE INTERACTION OF TEAD/TEF WITH YKI/YAP MEDIATES THE OUTPUT OF THE HIPPO PATHWAY
While it was known that Yki/YAP functions as a transcriptional co-activator since it lacks a DNA binding domain (Yagi et al., 1999) , the identity of its target transcription factor remained enigmatic. Several transcription factors were found to interact with Yki/YAP such as RUNX1/2 (Yagi et al., 1999) , ErbB4 (Komuro et al., 2003) , and p73 (Strano et al., 2001; Omerovic et al., 2004) ; but none was found to be functionally linked to the Hippo pathway. Although TEAD/TEF family transcription factors were identified as Yki/YAP partners as early as 2001 (Vassilev et al., 2001) , the functional link between the Hippo signaling pathway and the interaction of TEAD/TEF family transcription factors and Yki/YAP was established only recently in Drosophila and mammals (Goulev et al., 2008; Wu et al., 2008; Zhang et al., 2008) . In Drosophila, the TEAD/ TEF transcription factor Scalloped (Sd) mediates Hippo signaling in organ size control by functioning as a Yki partner. This interaction has been demonstrated both in vitro and in vivo (Goulev et al., 2008; Wu et al., 2008; Zhang et al., 2008 ). Inactivation of Sd shows similar phenotypes to a loss of Yki which is characterized by a suppression of tissue overgrowth and target gene expression caused by tumor suppressor mutations or Yki overexpression in the Hippo pathway, while an overexpression of Sd enhances tissue overgrowth (Wu et al., 2008; Zhang et al., 2008; Zhao et al., 2008) . Further evidence that supports the link between Yki and Sd comes from a Yki missense mutation that abrogates Sd-Yki binding as well as inactivates Yki function in vivo (Wu et al., 2008) . In mammalian cells, YAP is found to bind strongly to four TEAD homolog proteins (TEAD 1-4) both in vitro and in vivo, and this interaction mediates YAP-dependent gene induction and growth control in human and mouse cells Zhao et al., 2008) . Furthermore, TEAD1/2 double knockout mice are lethal and manifest proliferation defects similar to that of YAP knockout mice . Knockdown of TEAD1/3/4 also markedly shrank the enlarged acini caused by YAP-5SA expression . Further compelling evidence demonstrated that the YAP-S94A mutant, which lost its ability to physically interact with TEADs, abolishes its ability to activate TEADs for YAPinduced overgrowth, EMT and oncogenic transformation in MCF10A cells .
Although the functional conservation between Drosophila Sd-Yki complex and mammalian TEADs-YAP has been determined (Wu et al., 2008; Zhao et al., 2008) , the genes regulated by TEADs-YAP in mammals are different from those regulated by Sd-Yki. Cyclin E and IAP, which are the key Yki-inducible genes in Drosophila, were found to be not significantly induced by YAP in either mouse (i.e., NIH-3T3) or human cells (i.e., MCF10A) . This finding might indicate that although the key components of the Hippo pathway are conserved between Drosophila and mammals, the detailed mechanism between both species might have substantial differences.
STRUCTURAL STUDIES OF TEAD AND THE TEAD-YAP COMPLEX
TEAD/TEF transcriptional factors interact with the N-terminal of Yki/YAP via their C-terminals. Two recently determined structures clarified how TEAD mediates the function of YAPinduced gene expression Li et al., 2010) (Fig. 3B and 3C ). The first is the crystal structure of the Cterminal of mouse TEAD4 in complex with the N-terminal of mouse YAP (mouse TEAD4-YAP) (Fig. 3B) , and the other is the crystal structure of the C-terminal of human TEAD1 in complex with the N-terminal of human YAP (human TEAD1-YAP) (Fig. 3C) . In the structure of mouse TEAD4-YAP complex, TEAD4 adopts an immunoglobulin-like β-sandwich fold flanked by four short α helices, while YAP resembles a belt wrapped around TEAD4 via folding into two α helices linked by a PXX f P motif-containing loop. The structure of human TEAD1-YAP, as expected, is highly similar to the structure of mouse TEAD4-YAP. However, YAP in the human complex contains an additional N-terminal β strand and thus presents an extra recognition interface with the immunoglobulinlike β-sandwich fold in TEAD1. It is not surprising that deletion of this additional N-terminal β strand in hYAP had little effect on its interaction with human TEAD1 as a synthetic human YAP peptide encompassing both the α helices (amino acids 61-100) has been shown to be sufficient for binding to TEAD (Tian et al., 2010) . Structural comparison of the TEAD-YAP complex with the C-terminal fragment of human TEAD2 (Tian et al., 2010 ) revealed a lack of conformational rearrangements in TEAD upon binding to YAP (r.m.s.d. 0.75) (Fig. 3D) . The C-terminal of TEADs presented a rigid interface for specific interaction with YAP, while nuclear magnetic resonance (NMR) studies have revealed that the N-terminal TEAD binding domain of YAP exists in an unfolded conformation in its native state and that TEAD binding causes localized conformational changes in YAP (Tian et al., 2010) . More importantly, point mutation studies of TEAD4 based on the mouse TEAD4-YAP complex structure indicate that the residues important for YAP interaction are required for TEAD4 transforming activity on soft agar assay. Although the mouse TEAD4-YAP complex structure is highly similar to the structure of human TEAD1-YAP (r.m.s.d. 0.71), both structures have provided somewhat conflicting suggestions on the importance of a PXX f P motif, a loop conserved in YAP and the mammalian homolog Yki but not in TAZ. While it has emerged from the report by Chen et al. that this motif not only plays a pivotal role in the interaction with TEAD4, but also is crucial for YAP's transforming ability . Li et al. have downplayed this suggestion, indicating that the PXX f P motif contributes a minor role in binding TEAD . Although whether the PXX f P motif is a bona fide TEAD binding site remains to be rigorously tested, both structures have elucidated the structural basis for TEAD/YAP interaction.
Importantly, both structures have shed light on the etiology of SCRA. Apart from identifying the residues important for TEAD/YAP interaction through point mutations, these structures have explained the essential role of a tyrosine residue (Y422 in mTEAD4 and Y406 in hTEAD1), whose nonconservative missense mutation to a histidine has been implicated in this genetic disease (Fossdal et al., 2004) . This tyrosine was found to be involved in hydrogen bond interactions with a corresponding serine residue in YAP (S79 in mYAP and S94 in hYAP Li et al., 2010) . Mutation of this tyrosine residue in TEAD1 abolished its interaction with YAP and TAZ (Kitagawa, 2007) . Substitution of this residue by His or any other residue would disrupt its interaction with YAP and account for the observed biochemical and pathological phenotypes.
Given that the Hippo pathway is implicated in cancer and YAP is regarded as an oncogenic protein, the structures of TEAD and YAP may provide a new strategy for cancer therapeutics by disrupting the TEAD-YAP interaction. Both structures show that only a small fragment in the N-terminal region of YAP is involved in the interaction of TEAD, and that all the three important binding regions identified by Chen et al. (the two α helices and the PXX f P motif containing linker region) are required for interaction between YAP and TEAD and are hence crucial specificity determinants (unpublished data). Targeting the YAP binding surface on TEAD by either designing a peptide molecule that mimics the region of YAP bound to TEAD in the structure or a small molecule that selectively blocks any of the three important binding regions between YAP and TEAD might be an effective strategy to abolish the TEAD-YAP interaction and may have anticancer therapeutic potential.
FUTURE PERSPECTIVES
The past several years have witnessed rapid progress in Hippo pathway research. These advances made mainly by genetic and biochemical studies have greatly increased our understanding of the molecular mechanisms underlying the Hippo signaling pathway. Complementary to these studies, structural biology has been emerging as a key approach to reveal mechanistic insights into Hippo signaling. In addition to the structures of TEAD in isolation and in complex with YAP, the structures of several components of the Hippo pathway have been determined. These include Mats/Mob1 (PDB ID: 1PI1) (Stavridi et al., 2003) , Mst1 (PDB ID: 3COM), the Sav WW domain (PDB ID: 2YSB, 2DWV) (Ohnishi et al., 2007) , Merlin's FERM domain (PDB ID: 1ISN) (Shimizu et al., 2002) , the C2 domain of KIBRA (PDB ID: 2Z0U), and the UBA domain from mouse LATS2 (PDB ID: 2COS). Altogether these structures have extended our understanding of the molecular mechanism governing the Hippo pathway. However, many key questions remain to be addressed. The major future challenge is to identify the molecular nature of the upstream signals and to elucidate how these signals regulate the Kibra-Ex-Mer complex and trigger the core kinase cassette. Structural studies on the Kibra-Ex-Mer complex and its interaction with Hpo/Sav are required to reveal the mechanism underlying these processes.
Another outstanding question in the outputs of the pathway is how YAP coordinates its binding to TEAD with the binding of canonical M-CAT elements to TEAD to regulate target gene expression. M-CAT sequence motifs (5′-TCATTCCT-3′) are found in several muscle-specific gene promoters and are important for the regulation of these genes during embryonic development and disease (Larkin et al., 1996; Jiang et al., 2000) . TEADs contain an N-terminal TEA domain, which is a DNA binding module, and a C-terminal protein binding domain, which interacts with the N-terminal of YAP. The solution structure of the N-terminal TEA domain of TEAD has provided a model for how TEAD uses its N-terminal TEA domain to bind M-CAT elements (Anbanandam et al., 2006) , and the two TEAD-YAP complex structures explain how TEADs and YAP interact with each other Li et al., 2010) . Although the N-terminal of YAP has been shown to undergo a significant conformational change from its native unfolded form upon the binding of the C-terminal of TEAD, TEAD, on the other hand, has no conformational change occurring upon binding to YAP. It remains unknown how the full-length TEAD protein uses its two functional domains (TEA domain and YAP-binding domain) for binding to YAP and the M-CAT element simultaneously. The complex structure of the heterotrimeric TEAD, YAP and M-CAT motif would reveal the mechanism by which YAP modulates TEAD transcription activity to regulate target gene expression to control the output of the Hippo pathway. Finally, given that increased TAZ/YAP-TEAD activity is associated with diverse human cancers, inhibiting YAP/TAZ may offer a potential therapeutic strategy for treatment of human cancers.
ABBREVIATIONS
Ds, dachsous; Ex, expanded; FERM, F for 4.1 protein E for ezrin, R for rasixin and M for moesin.Ft; fat; Hpo, Hippo; Lats1, large tumor suppressor 1; Mats1, Mob as tumor suppressor; Mer, merlin; Sav, salvador; Sd, scalloped; TAZ, Transcriptional coactivator with PDZbinding motif; TEAD/TEF, transcription enhancer factor; Wts, warts; YAP, Yes-associated protein; Yki, Yorkie
